EP300 and central nervous system cancer: Previous studies have demonstrated that EP300‐mediated HSPA5 acetylation at K353 enhances resistance in pancreatic cancer cells [35], whereas dihydroartemisinin‐induced ERS mitigates iron death [36] in glioma cells through the PERK/ATF 4/HSPA5 pathway.